CalciMedica Releases Q2 2026 Financial Results
CalciMedica (CALC) reported a wider net loss of $7.7M, or $0.45 per share, for Q2 2026, an increase from $0.40 per share in Q2 2025. This reflects continued investment in its biopharmaceutical pipeline and the capital-intensive nature of clinical-stage development. Despite the losses, analyst …